Jang H, Hill NL, Turner J, Bratlee-Whitaker E, Jeong M, Mogle J. Poor-quality daily social encounters, daily stress, and subjective cognitive decline among older adults. Innov Aging. 2024 May 8. doi: 10.1093/geroni/igae038
Turner JR, Hill NL, Brautigam L, Bhargava S, Mogle J. How does exposure to dementia relate to subjective cognition? A systematic review. Innov Aging. 2023 Jun 19. doi: 10.1093/geroni/igad056
Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Bhargava S, Hill N, Mogle J. Self-reported memory problems are related to depressive symptoms in older adults with certain personality traits. Poster presented at the 2020 Gerontological Society of America (GSA) Annual Scientific Meeting; November 4, 2020. [abstract] Innov Aging. 2020 Dec 16; 4(Supplement_1,2020):389-90. doi: 10.1093/geroni/igaa057.1254
Mogle J, Hill N, Bhargava S, Bell T, Whitaker E. The factor structure of memory complaints over time. Poster presented at the Gerontological Society of America; November 2019. Austin, TX. [abstract] Innov Aging. 2019 Nov; 3(Supp 1):S221.
Hill NL, Mogle J, Bhargava S, Bell TR, Wion RK. The influence of personality on memory self-report among black and white older adults. Presented at the 2019 Gerontological Society of America (GSA) Annual Scientific Meeting; November 13, 2019. Austin, TX. [abstract] Innov Aging. 2019 Nov; 3(Suppl 1):S220.
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Rausch DA, Levin M, Meyers J, Candrilli S, Yan S, Krishnarajah G, Patterson B. Cost of diagnosed herpes zoster complications in patients age ≥50 years: a US claims data analysis. Poster presented at the IAGG 2017 World Congress; July 23, 2017. San Francisco, CA. [abstract] Innov Aging. 2017 Jul; 1(Suppl 1):902. doi: 10.1093/geroni/igx004.3234
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.